FinerLB, HenshawSK. Disparities in rates of unintended pregnancy in the United States, 1994 and 2001. Perspect Sex Reprod Health, 2006; 38:90–96.
2.
JickSS, HernandezRK. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. BMJ, 2011; 342:d2151.
3.
RaymondEG, BurkeAE, EspeyE. Combined hormonal contraceptives and venous thromboembolism: putting the risks into perspective. Obstet Gynecol, 2012; 119:1039–1044.
4.
U.S. Food and Drug Administration. Background Document for Joint Meeting of Advisory Committee for Reproductive Health Drugs and the Drug Safety and Risk Management Advisory Committee. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM282462.pdf. 2013 January 18.
5.
Yasmin package insert. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021098s022lbl.pdf. 2013 January 18.
6.
DingerJ, MinhTD, ButtmannN, BardenheuerK. Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen. Obstet Gynecol, 2011; 117:33–40.
7.
ArowojoluAO, GalloMF, LopezLM, GrimesDA. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev, 2012; 7:CD004425.
8.
SecuraGM, AllsworthJE, MaddenT, MullersmanJL, PeipertJF. The Contraceptive CHOICE Project: reducing barriers to long-acting reversible contraception. Am J Obstet Gynecol, 2010; 203:115.e111–117.
9.
CaseyPM, LongME, MarnachML. Abnormal cervical appearance: what to do, when to worry?Mayo Clinic Proc, 2011; 86:147–150quiz 151.
